RDIF and BGI Group announce strategic partnership in genetics industry
Beijing, April 25, 2019 - The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announces a strategic partnership with China’s BGI Group, one of the world’s leading companies in genetics industry. The corresponding agreement was signed today as part of Russian President Vladimir Putin’s visit to Beijing.
BGI Group is one of the world’s leaders in genetics offering proprietary equipment, reagents, tests and bioinformatics solutions. BGI Group is the operator and key partner of the China National GeneBank with over 20mn genetic samples.
The agreement is an important step in strengthening economic ties between Russia and China. It will also enable RDIF to attract new investment in Russia’s high-tech sector including breakthrough solutions in healthcare.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
“Joint efforts will allow us to take genetics to a new level. This partnership will contribute to the level of medical services in Russia and support an increase in the overall quality of life. The combination of RDIF’s investment expertise and BGI Group’s scientific and technological base provide broad opportunities for cooperation, including with the Fund’s partners from other countries”
Wang Jian, Co-founder and President of the BGI group, said:
"We are very exсited to partner with RDIF and bring our genomics technologies and solutions to benefit the community and people in Russia. By liasing our resource and platforms, we believe great value can be achieved in genomics industry.”
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 70 projects with foreign partners totaling more than RUB 1.5tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 700,000 people and generate revenues which equate to more than 5% of Russia’s GDP. RDIF established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40bn. Further information can be found at rdif.ru
About BGI Group
BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high profile research, which has generated more than 2,130 publications. BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own sequencing platform, economies of scale, and expert bioinformatics resources. BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare.
For additional information contact:
Russian Direct Investment Fund
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133